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Key words: ovarian cancer, BRCA, trabectedin introduction The completion of Cancer Genome Atlas Project (TGCA) [1] revealed that up to 50% of high-grade serous and endometrioid ovarian cancer present an impairment of homologous recombination (HR): 10%-15% because of germline mutation of BRCA 1-2 genes, 10% because of a somatic mutation of the same genes, up to 15% because of epigenetic inactivation of BRCA genes (especially due to loss of heterozygosity, LOH, or methylation process) and the remaining 10% because of malfunctioning of other genes involved in HR control (RAD 51C, Fanconi's anemia gene, pTEN, ATM, ATR, EMSY etc.). In this scenario, the identification of drugs particularly active in this subset of patients represents a priority of clinical research.
Trabectedin (ET-743, Yondelis®, PharmaMar, Madrid, Spain) is a marine-derived tetrahydroisoquinoline alkaloid with antitumor activity, approved in up to 65 nations as single agent for treatment of soft tissue sarcoma and in combination with pegylated liposomal doxorubicin (PLD) for relapsed ovarian cancer [2] . Originally identified as a DNA minor groove binding drug, actually trabectedin is considered to have multitasking mechanism of action and has been shown to selectively deplete blood monocytes and tumor-associated macrophages, suggesting that part of the antitumor activity of the drug could be ascribed to its ability to act as a tumor microenvironment modifier [3] .
Its covalent binding to N2 guanine at the minor DNA groove induces a bend to the major DNA groove which is recognized by the nucleotide excision repair (NER) system [4, 5] . These findings support the demonstration that, contrary to what shown for other DNA binding agents, a functional NER system seems necessary for efficient trabectedin cytotoxicity [4, 6] . Moreover, several evidence seem to suggest that trabectedin is particularly effective in cells lacking functional HR repair mechanisms, such as those endowed with BRCA gene mutation or BRCAness phenotype [5, 7, 8] . Preclinical data indicate that a functional transcription-coupled nucleotide excision repair (TC-NER) machinery and a deficient homologous recombination repair (HRR) machinery are required for in vitro sensitivity to trabectedin [8] .
The results from a retrospective analysis conducted in a cohort of 92 paraffin-embedded tumor tissue from sarcoma patients treated with trabectedin showed the association of low tumor BRCA1 mRNA expression levels with a higher percentage of patients free of disease progression at 6 months (33% versus 11%, P = 0.02) and a longer median survival (15 versus 5 months, P = 0.0003) than patients with high expression [7] . Based on these observations, it was hypothesized that the NER machinery trapped in the DNA lesion induced by trabectedin was resolved by the cells producing double-strand breaks that were repaired by the HRR machinery, and according to the model proposed by these authors, synergistic action of TC-NER and HRR machinery would be necessary for maximal trabectedin cytotoxicity [8] .
This prospective phase II trial was designed to evaluate the activity of trabectedin as single agent in the treatment of recurrent ovarian cancer (ROC) patients presenting BRCA mutation and/or BRCAness phenotype. Moreover, the activity of the drug has been analyzed with respect to a series of polymorphisms which seem particularly involved, according to literature data, in DNA gene repair and components of NER complex [9] .
patients and methods
This is a prospective, multicenter, non-randomized single-arm trial. Patients with recurrent germline BRCA-mutated ovarian cancer and/or BRCAness phenotype were prospectively enrolled and treated with trabectedin 1.3 mg/ mq in 3 h i.v. every 3 weeks through a central line. The BRCAness phenotype defines a population of patients with repeated (at least 2) previous response to platinum. Patients were stratified according to the sensitivity to the last platinum treatment [PFI; platinum-resistant (PR) patients were defined as patients with a PFI <6 months, whether platinum-sensitive (PS) were defined as patients with a PFI > 6 months], and PS patients were enrolled if they were not willing or not able to receive other platinum treatments. Other inclusion criteria were: age ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, measurable disease, life expectancy >3 months, absolute neutrophil count (ANC) >1500/mm 3 ; platelets count >100 000/mm 3 ; bilirubin and creatinine levels <1.5 times the upper limit of normal; normal cardiac function defined as LVEF ≥50%. The trial was approved by the Ethical Committee of each participating institutions. Pretreatment evaluation included pelvic examination, abdomino-pelvic CT scan, serum Ca 125 evaluation. Trabectedin (Yondelis®, PharmaMar) was supplied as a lyophilized powder in glass vials of 0.25 or 1 mg and administered as a 3 h infusion. Premedication with corticosteroids as prophylaxis against hepatic toxicity was done according to clinical guidelines [10] . Cycles were administered every 21 days until disease progression or unacceptable toxicity or patients refusal to continue treatment, whichever occur first. The criteria for retreatment on day 1 of each cycle were complete recovery of hematological toxicity and recovery of non-hematological toxicity to less than G1. In the case of prolonged (>5 days) G4 neutropenia and febrile G3 neutropenia and in the case of ≥ grade 3 non haematologic toxicity, trabectedin dose had to be reduced to 1.1 mg/mq. No more than two dose reductions for toxicity were allowed. The primary end point of the trial was response rate. All patients receiving at least one trabectedin infusion were considered assessable toxicity. Treatment-related toxicity was assessed according to NCI-CTC criteria version 4.3 [11] . Treatment response was evaluated according to RECIST version 1.1 criteria [12] every three cycles. In the case of response, a confirmatory CT scan after 28 days was carried out. In a conservative way, patients reporting deterioration of clinical symptoms before radiologic evaluation were considered to have progressive disease. In patients with CA 125 elevation above UNL, response was also evaluated according to GCIG criteria [13] .
Progression-free survival (PFS) was defined as the time interval between the first trabectedin treatment and the documented radiologic progression, and overall survival (OS) as the time interval from the first study drug infusion to the death. Patients still alive at the time of the data lock were censored at the last contact. [14] . Sample resulting as positive at the fragments analysis were not sequenced by NGS but directly processed using targeted Sanger sequencing approach involving the altered region found. All samples which resulted as negative to fragments analysis were run by NGS.
After sequencing run, the GS Junior software generates Standard Flowgram Format (sff ) file. Amplicon Variant Analyzer v 2.7 (AVA) (Roche Diagnostics), supplied with the GS Junior instrument, aligns the sequencing reads to the reference sequences NG_ 005905.2 and NG_012772.1 for BRCA1 and BRCA2 genes, respectively.
DNA extraction and single-nucleotide polymorphisms genotyping
Genomic DNA was extracted from whole blood samples (350 µl) using the QIAamp DNA blood extraction kit on Biorobot EZ1 instrument (Qiagen, Milan, Italy) according to the manufacturer's instructions. Single-nucleotide polymorphism (SNPs) of three genes: ERCC1 Asn118Asn, ERCC1 C8092A, XPD Lys751Gln, XPD Asp312Asn and XPG Asp1104His, were studied with Taqman probe-based assays using primers and probe sequence purchased from Life Technologies. Fluorescence in each sample was measured before and after PCR using ABI Prism 7300 Sequence Detection System. Data were analyzed using the Allelic Discrimination Program with SDS 2.3 software (Applied Biosystems, Foster City, CA).
statistical analysis
A level of interest of antitumor activity of 15% and 30% was estimated for PR and PS patients, respectively. Sample size was determined using a Simon 2-stage minimax design, with a type I and II error of 0.05 and 0.20, respectively.
For the PS group, 23 patients were enrolled in the first stage. If at least 4 responders were observed, ∼25 additional patients were enrolled. In the PR group, 30 patients were enrolled in the first stage. If at least 2 responders were observed, ∼22 additional patients were enrolled. 
patients characteristics
Between February 2012 and August 2013, 100 patients were registered in 9 Italian institutions; 1 patient was a screening failure, thus leaving 99 patients enrolled (Table 1) : 3 patients withdrew the informed consent soon after protocol registration, and in 2 patients, the radiologic evaluation after 3 cycles was not done due to patient refusal because of poor performance status, thus leaving 94 patients evaluable for RECIST assessed response. At the time of study entry, 51 (50.5%) patients were defined as resistant to the last platinum treatment, and 48 were defined as still sensitive (49.5%). The vast majority of patients had serous tumors (n = 86, 86.9%), and 54 of them were high-grade tumors; the median number of previous chemotherapy lines was 4 (range = 2-14), and 48.5% of patients had already received ≥3 prior platinumbased treatments.
response to treatment
As of January 2015, the median follow-up was 44 weeks (range 5-136). All patients had measurable disease. As shown in Table 2 , in the whole population, 4 complete and 33 partial responses were registered for an overall response rate (ORR) of 39.4%, and an overall clinical benefit (RR+SD) of 63.8%. In the PR population, an ORR of 31.2% and an overall clinical benefit of 54.2% were registered; the corresponding figures for the PS patients were 47.8%, and 73.9%, respectively. In 'platinum refractory' patients (n = 11), response to trabectedin treatment was progression of disease in nine patients, stable disease in one patient and partial response in one patient.
Among variables associated with RECIST defined response, only GCIG-assessed response was found to be associated with RECIST assessed response (see supplementary Table S1 , available at Annals of Oncology online). We also analyzed the rate of response in high-grade serous versus other histotypes: there was no difference between the two groups (data not shown).
survival analysis
Follow-up data were available for 96 patients: progression and death of disease were observed in 83 (86.4%), and 42 (43.7%) cases, respectively.
In the whole series, the median PFS with trabectedin was 18 weeks [95% confidence interval (CI) [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , and the median OS was 72 weeks (95% CI = 48-nr) (Figure 1) .
Previous PFS to the last platinum treatment was associated with duration of PFS with trabectedin: PS patients (median duration of PFS after the last platinum based treatment = 11 months, range 7-45), showed a more favorable PFS with trabectedin (median = 24 weeks, 95% CI 18-32) than PR patient (median duration of PFS after the last platinum = 5.5 months, range 1-6); in the latter group, the median PFS with trabectedin was 12 weeks, 95% CI 9-22; P-value = 0.049; Figure 2A) .
A statistically significant longer OS was also found in PS compared with PR patients ( Figure 2B ).
translational study
Data about germline mutational status of BRCA 1/2 genes were available for 74 patients: 15 cases were BRCA1 gene mutated (20.0%), 6 cases were BRCA2-mutated (8.0%) and 5 cases presented variants of unknown significance (VUS) (supplementary Table S2 , available at Annals of Oncology online). Of 21 patients harboring germline BRCA mutation, 13 patients had not experienced >2 previous response to platinum.
Cases with VUS were not considered in the analysis of distribution of RECIST assessed response, thus leaving 69 patients for the evaluation of response according to BRCA gene mutational status ( supplementary Table S3 , available at Annals of Oncology online): in the wild-type population, objective response and clinical benefit were found in 19 (39.6%), and 32 (66.7%) of cases, while the corresponding figures in BRCA-mutated patients were 39.6% and 76.2%, respectively. There was no statistically significant difference in ORR and clinical benefit according to the mutational status.
Data about the distribution of response according to the status of 5 SNPs involved in NER machinery (ERCC1 C1148T, ERCC1 C8092, XPG ASP1104HIS, XPD ASP312ASN, XPD LYS751GLN) were available in 71 cases (supplementary Table S3 , available at Annals of Oncology online): there was no association between SNPs abnormality and response to trabectedin.
There was no difference in PFS and OS in the whole series according to BRCA 1-2 status ( supplementary Figure S1 , available at Annals of Oncology online). Similar findings were documented for SNPs involved in NER machinery (data not shown).
details on treatment and toxicity
Details on trabectedin treatment are reported in Table 3 : a cumulative number of 577 cycles, and a median cumulative dose of 11.1 mg/mq of trabectedin were administered (median = 6 cycles/patient). In 29 patients (29%), the dose of trabectedin was reduced to 1.1 mg/mq, and in more than 70% of cases, reduction was required because of hematologic toxicity. The most frequent reason for treatment discontinuation was progression of disease, while patient's and physician's choice contributed for 18% and 2% of cases, respectively.
The worst hematological and non-hematological toxicity per patient is reported in Table 4 : as expected, myelotoxicity was the prevalent toxicity with 22% of patient experiencing grade 4 neutropenia, and 9.1% and 10.1% of patients reporting grade 3-4 anemia and thrombocytopenia, respectively. Nausea and vomiting and asthenia were the most frequent non-hematologic events (grade ≥2 26.2% and 49.5% of patients, respectively), discussion This is the first prospective trial specifically addressing the role of trabectedin in BRCA-mutated and/or in BRCAness phenotype ROC patients. The ORR of 39.4% with an overall clinical benefit of 63.8% in a population who has received a median of four previous chemotherapy lines appears as an outstanding result. Several retrospective series have pointed out the particular efficacy of trabectedin in PS patients [15] , and in a previous experience, our group reported a 27.5% response rate and a 61.2% clinical benefit in a population who had received at least four previous chemotherapy lines [16] . Our data prospectively confirmed that the signature of 'repeated platinum sensitivity' identifies patients highly responsive to trabectedin. In this setting, the activity of trabectedin seems comparable to what obtained using platinum compounds [17] , and the drug may represent a valuable alternative option in patients who present contraindication to receive platinum (cumulative neurotoxicity or renal failure) or are unable to receive again platinum compounds because of hypersensitivity reaction which impact in up to 44% of patients at platinum reintroduction [18] .
It has been suggested that, given the peculiar mechanism of action, trabectedin may be particularly effective in BRCAmutated patients [5, 7, 8] . Previous experiences on sarcoma patients [5] seem to suggest an association between low tumor BRCA1 mRNA expression and an higher percentage of patients progression-free at 6 months (33% versus 11%, P = 0.02) and a longer median survival (15 versus 5 months, P = 0.0003) . In a phase II trial, Delaloge et al. [8] reported 17% response rate and 40% clinical benefit in a population of 40 heavily pretreated, BRCA1/2 mutated, breast cancer patients concluding that the drugs deserved further evaluation in patients selected for BRCA mutation.
Monk et al. [19] investigated the association of BRCA1 and XPG mutations with response rate, PFS and OS in a subset of patients from the phase 3 clinical trial OVA 301 comparing the efficacy and safety of trabectedin plus PLD versus PLD alone in patients with ROC. Overall, 41 (16%) of the 264 women had BRCA1(mut) and 17 (6%) had XPG(mut). A higher RR was observed in BRCA1(mut) patients (49%) versus BRCA1(wt) patients (28%). Within the BRCA1(mut) group, trabectedin + PLD-treated patients had longer PFS and longer OS than PLDtreated patients (median PFS 13.5 versus 5.5 months, P = 0.0002; median OS 23.8 versus 12.5 months, P = 0.0086), whereas in BRCA1(wt) patients, OS was not significantly different. There were no differences in OS or PFS according to XPG (mut) between the two treatment arms.
In our study, the percentage of BRCA-mutated (28.0%) seems higher with respect to what reported in the general population (germline mutation prevalence 10%-15%) [20] .
Several earlier studies have reported that ovarian cancer patients with germline BRCA mutations have improved survival when compared with wild-type patients and this is possibly due to an enhanced sensitivity to platinum [21] ; therefore, it is not surprising that in our population, selected according to the clinical criteria of repeated platinum sensitivity, there is an enriched number of BRCA-mutated patients.
Moreover, in our study, the ORR of BRCA-mutated patients, although elevated, is not significantly higher than that registered in the wild-type population. This is possibly related to the small number of patients; however, it cannot be excluded that the assessment of somatic BRCA mutation could be of help in the future. Finally, it has to be taken into account that germline and somatic BRCA mutations are not the only mechanisms controlling the HR [1] . The complexity of the machinery involved in HR could explain why in our population the 'single assessment' of germline mutation of BRCA genes seems not significantly predict trabectedin sensitivity. Probably, these are also the reasons explaining why we were unable to find any correlation between SNPs involved in DNA repair genes and NER machinery in particular, and clinical outcome in patients treated with trabectedin.
In our experience, the toxicity profile of the drug seems not different with respect to what already reported [22] : however, the rate of some toxicities (e.g. hematological and liver toxicity) is not negligible, being, nonetheless, expected given the median number of chemotherapy lines administered to our patients before trabectedin treatment. In our population, no cardiac toxicity was reported, thus confirming the cardiac safety of trabectedin [23] , although our patients presented preexisting comorbidities (hypertension, cardiac disease and diabetes in 35.2%, 11.3% and 5.6% of cases, respectively) which might impact on the cardiac safety profile of the drug.
A great limitation of our study is the single-arm design with the absence of a comparator treatment but, the interesting results of this phase 2 trial, prompted us to design and launch a randomized phase III trial in the same population in which trabectedin is compared with all the available chemotherapies at physician' choice (MITO 23 trial).
In conclusion, our results suggest that patients with BRCAness phenotype may receive benefit with trabectedin treatment at the price of an acceptable safety profile. Very recently, the CHMP of EMA approved olaparib, the first poly ADP-ribose polymerase inhibitor (PARP), for the treatment of recurrent, PS ovarian cancer as maintenance after at least two platinum treatments based on a 4 months increase in the median PFS with respect to placebo [24] . Although apparently non-confirmed [25] , preclinical models seem to suggest a reduction in the likelihood of response to subsequent chemotherapy following olaparib treatment because of development of cross-resistance between PARPi and platinum-based therapies through the acquisition of secondary mutations that restore the BRCA1/2 protein expression [26] . In this scenario, the availability of other active DNA alkylating agents may represent an opportunity of care for the patients. references
